Pneumology Service, San Pedro de Alcantara Hospital, Cáceres, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Thorax. 2018 Apr;73(4):361-368. doi: 10.1136/thoraxjnl-2017-210642. Epub 2017 Nov 16.
Despite a significant association between obesity hypoventilation syndrome (OHS) and cardiac dysfunction, no randomised trials have assessed the impact of non-invasive ventilation (NIV) or CPAP on cardiac structure and function assessed by echocardiography.
We performed a secondary analysis of the data from the largest multicentre randomised controlled trial of OHS (Pickwick project, n=221) to determine the comparative efficacy of 2 months of NIV (n=71), CPAP (n=80) and lifestyle modification (control group, n=70) on structural and functional echocardiographic changes.
Conventional transthoracic two-dimensional and Doppler echocardiograms were obtained at baseline and after 2 months. Echocardiographers at each site were blinded to the treatment arms. Statistical analysis was performed using intention-to-treat analysis.
At baseline, 55% of patients had pulmonary hypertension and 51% had evidence of left ventricular hypertrophy. Treatment with NIV, but not CPAP, lowered systolic pulmonary artery pressure (-3.4 mm Hg, 95% CI -5.3 to -1.5; adjusted P=0.025 vs control and P=0.033 vs CPAP). The degree of improvement in systolic pulmonary artery pressure was greater in patients treated with NIV who had pulmonary hypertension at baseline (-6.4 mm Hg, 95% CI -9 to -3.8). Only NIV therapy decreased left ventricular hypertrophy with a significant reduction in left ventricular mass index (-5.7 g/m; 95% CI -11.0 to -4.4). After adjusted analysis, NIV was superior to control group in improving left ventricular mass index (P=0.015). Only treatment with NIV led to a significant improvement in 6 min walk distance (32 m; 95% CI 19 to 46).
In patients with OHS, medium-term treatment with NIV is more effective than CPAP and lifestyle modification in improving pulmonary hypertension, left ventricular hypertrophy and functional outcomes. Long-term studies are needed to confirm these results.
Pre-results, NCT01405976 (https://clinicaltrials.gov/).
尽管肥胖低通气综合征(OHS)与心功能障碍之间存在显著关联,但尚无随机试验评估无创通气(NIV)或 CPAP 对超声心动图评估的心脏结构和功能的影响。
我们对最大的 OHS 多中心随机对照试验(Pickwick 项目,n=221)的数据进行了二次分析,以确定 NIV(n=71)、CPAP(n=80)和生活方式改变(对照组,n=70)治疗 2 个月对结构性和功能性超声心动图变化的比较疗效。
在基线和 2 个月时获得常规经胸二维和多普勒超声心动图。每个站点的超声心动图医师均对治疗臂不知情。使用意向治疗分析进行统计分析。
基线时,55%的患者有肺动脉高压,51%的患者有左心室肥厚的证据。NIV 治疗而非 CPAP 治疗可降低收缩期肺动脉压(-3.4mmHg,95%CI -5.3 至-1.5;调整后 P=0.025 与对照组,P=0.033 与 CPAP)。基线时患有肺动脉高压的 NIV 治疗患者的收缩期肺动脉压改善程度更大(-6.4mmHg,95%CI -9 至-3.8)。只有 NIV 治疗可减少左心室质量指数,从而显著减少左心室质量指数(-5.7g/m;95%CI -11.0 至-4.4)。经过调整分析,NIV 在改善左心室质量指数方面优于对照组(P=0.015)。只有 NIV 治疗可显著改善 6 分钟步行距离(32m;95%CI 19 至 46)。
在 OHS 患者中,与 CPAP 和生活方式改变相比,NIV 的中期治疗在改善肺动脉高压、左心室肥厚和功能结局方面更为有效。需要进行长期研究来证实这些结果。
预结果,NCT01405976(https://clinicaltrials.gov/)。